HER2-Positive Gastric Cancer

Global HER2-Positive Gastric Cancer Market to Reach US$322.4 Million by 2030

The global market for HER2-Positive Gastric Cancer estimated at US$222.1 Million in the year 2024, is expected to reach US$322.4 Million by 2030, growing at a CAGR of 6.4% over the analysis period 2024-2030. Chemotherapy, one of the segments analyzed in the report, is expected to record a 7.2% CAGR and reach US$139.3 Million by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$60.5 Million While China is Forecast to Grow at 10.2% CAGR

The HER2-Positive Gastric Cancer market in the U.S. is estimated at US$60.5 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$66.8 Million by the year 2030 trailing a CAGR of 10.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.2% CAGR.

Global HER2-Positive Gastric Cancer Market - Key Trends & Drivers Summarized

How Is HER2 Positivity Changing the Landscape of Gastric Cancer Diagnosis?

HER2-positive gastric cancer refers to a subset of gastric and gastroesophageal junction cancers that exhibit overexpression of the HER2 (Human Epidermal Growth Factor Receptor 2) protein. While HER2 is more commonly associated with breast cancer, its role in gastric cancer is gaining recognition due to its predictive value for targeted therapy. Accurate diagnosis of HER2 status is now a key step in stratifying patients and guiding treatment regimens, particularly in advanced or metastatic cases.

Testing for HER2 positivity is conducted using immunohistochemistry (IHC) and confirmed with in situ hybridization (ISH) techniques. Global oncology guidelines recommend HER2 testing in newly diagnosed advanced gastric cancer patients to determine eligibility for HER2-targeted therapy. This has led to increasing integration of molecular profiling into clinical practice, with an emphasis on precision diagnostics to personalize treatment strategies and improve prognosis.

What Targeted Therapies Are Being Used or Developed for HER2-Positive Gastric Cancer?

Trastuzumab is the most established targeted therapy used for treating HER2-positive gastric cancer. Administered in combination with chemotherapy, it has shown improved survival outcomes in patients with HER2 overexpression. Following its approval for gastric cancer, the scope of HER2-targeted treatments has expanded, with newer agents under investigation including antibody-drug conjugates, bispecific antibodies, and tyrosine kinase inhibitors.

Advanced biologics such as trastuzumab deruxtecan are being tested in patients who are resistant to first-line therapies, showing promise in clinical trials for improved efficacy. Combination therapies that integrate immunotherapy with HER2-targeted drugs are also under evaluation. These innovations reflect a growing pipeline of personalized treatments tailored to HER2 expression profiles and tumor characteristics in gastric cancers.

Where Is Demand for Testing and Treatment Growing, and Who Are the Key Stakeholders?

Adoption of HER2 testing and targeted therapy is growing across oncology centers, academic hospitals, and diagnostic laboratories. Demand is strongest in regions with high gastric cancer incidence, such as East Asia, parts of Eastern Europe, and Latin America. Japan, South Korea, and China represent major diagnostic and therapeutic markets due to well-developed cancer care systems and high testing penetration.

Stakeholders include oncologists, pathology laboratories, pharmaceutical companies, and diagnostic assay developers. Collaborations between diagnostic firms and drug manufacturers are supporting the development of companion diagnostics and therapy-linked assays. National cancer control programs and public health initiatives are further encouraging HER2 screening as part of broader efforts to improve cancer survival rates through biomarker-driven treatment models.

What Is Driving Growth in the HER2-Positive Gastric Cancer Market?

Growth in the HER2-positive gastric cancer market is driven by several factors including rising incidence of gastric cancer, increasing use of biomarker-based treatment planning, and expanding access to HER2-targeted therapies. Advances in diagnostic precision, including improved antibody-based tests and automated pathology workflows, are supporting accurate HER2 identification.

End-use expansion in oncology treatment centers, diagnostic labs, and personalized drug development programs is strengthening market adoption. Pipeline growth of HER2-directed biologics, extended indications of existing drugs, and supportive clinical guidelines are reinforcing therapeutic relevance. As personalized oncology continues to evolve, HER2 testing and therapy are expected to play a central role in managing a biologically distinct segment of gastric cancer patients.

SCOPE OF STUDY:

The report analyzes the HER2-Positive Gastric Cancer market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Treatment Type (Chemotherapy, Targeted Therapy, Immunotherapy, Combination Therapies); End-User (Hospitals End-User, Specialty Cancer Centers End-User, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

• Acepodia Biotech Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Bavarian Nordic A/S
• Bellicum Pharmaceuticals
• BioInvent International AB
• Bristol-Myers Squibb
• Carisma Therapeutics Inc.
• Celularity Inc.
• Daiichi Sankyo Co., Ltd.
• Genentech (Roche Group)
• GeneQuantum Healthcare
• Hengrui (Jiangsu HengRui Medicine)
• Imugene Limited
• Klus Pharma Inc.
• MacroGenics, Inc.
• Merck & Co., Inc.
• Mersana Therapeutics, Inc.
• Novartis AG
• Pfizer Inc.
• Pieris Pharmaceuticals, Inc.
• Shanghai Miracogen Inc.
• Zymeworks Inc.

AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.